Protein tyrosine phosphatase (PTP) ⑀ (PTP⑀) exists as 2 forms generated by alternative promoter usage. It has recently been reported that a cytosolic isoform of PTP⑀ (PTP⑀C) when over-expressed in murine M1 myeloid cells inhibits interleukin-6 (IL-6)-and leukemia inhibitory factor-induced activation of Janus kinsases (JAKs), thereby suppressing STAT3 tyrosine phosphorylation and STAT3 signaling. This study characterizes an inhibitory action of PTP⑀C on IL-6 signaling and also reveals that PTP⑀C inhibitory activity is independent of other potential negative regulators, such as SHP-2 and SOCS family proteins. 
Introduction
Numerous cellular functions, such as growth, differentiation, and cell death, are regulated by cytokines. It is well established that the Janus kinase (JAK)-STAT signaling pathway plays a pivotal role in signal transduction via cytokine receptors. [1] [2] [3] [4] To date 7 members of the STAT family of proteins have been identified in mammals, and each STAT protein has been implicated in intracellular signaling elicited by distinct cytokines. 5 It has been shown that phosphotyrosine-based motifs residing in receptor subunits determine which particular STAT(s) is activated by a specific cytokine. 6 Although the mechanisms of signal transmission through the JAK-STAT pathway have been extensively studied, negative regulation of such signaling has thus far not been well characterized. Studies have identified a suppressors of cytokine signaling (SOCS)/STAT-induced STAT inhibitor (SSI)/cytokine-inducible SH2-containing protein (CIS) family of proteins that inhibits cytokine-induced JAK-STAT signaling(s). [7] [8] [9] Because SOCS/SSI/CIS expression is cytokine inducible, this family of proteins is supposed to form a negative feedback loop in cytokine signaling.
Interleukin-10 (IL-10) is an 18-kD polypeptide that is mainly secreted from helper T cells, B cells, thymocytes, keratinocytes, activated monocytes, and macrophages. 10 IL-10 acts on natural killer cells, B cells, T-helper lymphocyte 1 cells, monocytes, and macrophages to down-regulate and/or to limit their inflammatory and immune responses. 10, 11 On binding of IL-10 to the IL-10 receptor (IL-10-R), which belongs to the class II cytokine receptor family, 12, 13 receptor-associated JAK tyrosine kinases are activated and stimulate downstream signaling. 14-18 JAK1, tyrosine kinase 2 (TYK2), and STAT3 are all involved in this signaling cascade. 17, 19 Activated STAT3 protein, for example, translocates to the nucleus and regulates specific gene expression.
Protein tyrosine phosphatase (PTP) ⑀ (PTP⑀) exists as 2 forms generated by alternative promoter usage from a single gene: a transmembrane (PTP⑀M) and a cytosolic (PTP⑀C) form (PTP⑀C is also referred to as cyt-PTP⑀.). [20] [21] [22] Although PTP⑀M is expressed in brain, testis, and lung, expression of PTP⑀C is mainly restricted to hematopoietic tissues such as spleen, thymus, and peritoneal macrophages. 21, 22 PTP⑀C expression is up-regulated during differentiation and/or activation of macrophages. 21, 22 Peretz et al 23 have reported that PTP⑀C/cyt-PTP⑀ is also expressed in Schwann cells. Targeted disruption of the PTP⑀ gene in mice (both isoforms are disrupted) revealed its essential role in regulation of myelination of Schwann cells. 23 The role of PTP⑀C/cyt-PTP⑀ in other cell types remains obscure.
Recently, we reported that forced expression of PTP⑀C suppresses IL-6-and leukemia inhibitory factor (LIF)-induced JAK activation of murine M1 leukemia cells. 24 In this study, to further define the molecular mechanism of this suppression, we characterized PTP⑀C-mediated suppression of IL-6 signaling and examined whether PTP⑀C is a general inhibitor of cytokine signaling. We found that PTP⑀C-mediated suppression is selective for certain JAK-STAT signaling pathways through corresponding cytokine receptors such as gp130 and IL-10-R.
These findings shed light on the regulatory mechanisms of cytokine signaling.
Materials and methods

Materials
Murine interferon ␥ (IFN-␥) and IFN-␤ were generous gifts of Dr T. Abo (Niigata University) and Dr T. Minagawa (Hokkaido University), respectively. Human IL-6 was provided by Ajinomoto (Yokohama, Japan). Mouse IL-10 was purchased from Peprotech (London, United Kingdom). Specific antibodies to phosphotyrosine 701 of STAT1 and STAT1 were obtained from New England Biolabs (Beverly, MA).
IL-10 binding assay
The levels of IL-10-Rs on the cells were assessed by an IL-10-R detection kit (Genzyme, Minneapolis, MN), following the instructions of the manufacturer. The signal due to binding of biotinylated IL-10 was almost completely abolished by addition of 5-fold excess of nonbiotinylated mouse IL-10 (data not shown).
Stable transfectants
Establishment of M1 clones stably expressing PTP⑀C or PTP⑀C-DA has been described elsewhere. 24 In every experiment, 2 to 3 independent clones of passage 5 to 20 were analyzed. Results using representative clones, M1-⑀C-8 and M1-⑀C-DA-15, are shown throughout unless otherwise described. Cells were cultured in RPMI 1640 medium (Gibco-BRL, Rockville, MD) supplemented with 10% fetal calf serum (FCS; Intergen, Purchase, NY), 2 mM glutamate, 250 g/mL Geneticin (Gibco-BRL), streptomycin, and penicillin.
Northern blot analysis
Total RNAs prepared from cell lines treated with cytokines were analyzed by Northern blotting as described previously. 25 Probes used were mouse interferon regulatory factor 1 (IRF-1) complementary DNA (cDNA), 24 mouse Fc␥RI cDNA (nucleotides 680-1221), mouse SOCS-1 cDNA (nucleotides 275-650), and mouse SOCS-3 cDNA (nucleotides 440-872). NIH3T3 cells were cultured in Dulbecco modified Eagle medium (Sigma, St Louis, MO) supplemented with 10% FCS.
Western blot analysis
Cells were treated with 10 ng/mL IL-6 for 10 minutes, 25 ng/mL IFN-␥ for 30 minutes, or 20 ng/mL IL-10 for 20 minutes. Immunoprecipitation and Western blot analysis were done as described previously. 24 
Results
IL-6-induced activation of STATs in M1 cells expressing wild-type and a dominant-negative form of PTP⑀C
We previously reported that PTP⑀C negatively regulates IL-6-and LIF-induced JAK-STAT signaling when overexpressed in murine M1 cells. 24 Specifically, activation of STAT3 is impaired in M1 cells expressing PTP⑀C (M1-⑀C). By contrast, in cells expressing a catalytically inactive form of PTP⑀C, PTP⑀C-DA (M1-⑀C-DA), IL-6 activation of STAT3 was enhanced compared with parent M1 cells and mock-transfected (M1-Neo) cells. 24 These results further suggest that PTP⑀C-DA may act as a dominant negative and that endogenous PTP⑀C negatively regulates IL-6-induced JAK-STAT signaling. Studies have identified a SOCS/SSI/CIS family of proteins that inhibits cytokine-induced JAK-STAT signaling(s). [7] [8] [9] In the SOCS/SSI/CIS family, SOCS-1 and SOCS-3 have been shown to inhibit JAK-STAT signaling induced by IL-6. 7,9,26-29 PTP⑀C may function in the up-regulation of protein(s) of the SOCS family. If so, SOCS expression might be observed in M1-⑀C cells even under unstimulated conditions. To address this question, the steady state levels of SOCS-1 and SOCS-3 messenger RNA (mRNA) in M1-stable clones were determined ( Figure 1 ). Expression of SOCS-1 mRNA was not detected in all clones before IL-6 stimulation. IL-6 treatment of M1-Neo cells was accompanied by up-regulation of SOCS-1 mRNA. In M1-⑀C cells, IL-6-mediated up-regulation of SOCS-1 mRNA was reduced. These results are consistent with the previous report that IL-6-induced expression of SOCS-1 mRNA is under the control of STAT3, and IL-6-induced activation of STAT3 is suppressed in M1-⑀C cells. 9, 24 Additionally, expression of SOCS-3 mRNA was very low in M1 stable clones before and after IL-6 treatment, whereas they were highly expressed in IFN-␥-treated NIH3T3 cells as reported 30 (Figure 1 ). Taken together, these results suggest that negative regulation of cytokine signaling by PTP⑀C is independent of SOCS family proteins.
To characterize PTP⑀C-mediated regulation of STAT3, a time course of STAT3 phosphorylation/activation induced by IL-6 in M1-⑀C and M1-⑀C-DA cells was undertaken (Figure 2 ). PTP⑀C and PTP⑀C-DA produced delayed and earlier onset of STAT3 tyrosine phosphorylation following IL-6 stimulation, respectively, suggesting that PTP⑀C may work as a negative regulator at the onset of STAT3 tyrosine phosphorylation. Another PTP SHP-2 has been reported to be involved in negative regulation of gp130 signaling. [31] [32] [33] Introduction of a point mutation into gp130 that abrogates recruitment of SHP-2 apparently resulted in loss of this negative regulation and in prolonged activation of STAT3 without affecting the onset. 31, 33 These results suggest different modes of action for the 2 PTPs, PTP⑀C and SHP-2. 31, 33 Although STAT1 was activated by IL-6 to a lesser extent than was STAT3, the activation was gp130-tyrosine phosphorylationdependent. 34, 35 Therefore, the effect of PTP⑀C on STAT1 activation For personal use only. on September 13, 2017. by guest www.bloodjournal.org From was analyzed. STAT1 phosphorylation in M1-Neo cells was undetectable under our experimental conditions. However, in M1-⑀C-DA cells, IL-6 induced tyrosine phosphorylation of STAT1 (Figure 3 ). This experiment showed that PTP⑀C negatively regulates the activation of STAT1 as well as that of STAT3.
Negative regulation of IL-10 signaling by PTP⑀C
Because the JAK-STAT signaling pathway is used by many cytokines, it was important to analyze whether the inhibitory effect of PTP⑀C was specific to signaling induced by IL-6. We therefore investigated the effect of PTP⑀C on IL-10-induced signaling because JAK1, TYK2, and STAT3 are involved in IL-10 signaling as in IL-6-signaling cascade. 17, 19 First, we determined whether IL-10-Rs were expressed on M1-⑀C and M1-⑀C-DA cells by an IL-10 binding assay. As shown in Figure 4A , these cells bound IL-10 to a similar extent as mock-transfected M1-Neo cells, suggesting similar levels of receptor expression on the surface of all the stable clones. Stable clones were treated with IL-10 for 20 minutes and analyzed for STAT tyrosine phosphorylation. As illustrated in Figure 4B , IL-10 treatment preferentially induced tyrosine phosphorylation of STAT3 in M1-Neo cells. At the same time, STAT1 tyrosine phosphorylation was barely detected (data not shown). In M1-⑀C cells, the level of tyrosine phosphorylation of STAT3 by IL-10 was lower than that seen in M1-Neo cells.
It has been shown that IL-10 up-regulates expression of the Fc␥RI gene through STAT3 activation. 16, 36, 37 To determine whether a downstream target of STAT3 induced by IL-10 was also suppressed in M1-⑀C cells, cells were treated with IL-10 and subjected to Northern blot analysis to determine whether the Fc␥RI gene is up-regulated ( Figure 4C) . A treatment of M1-Neo cells with IL-10 resulted in a slight increase in Fc␥RI mRNA compared with untreated controls ( Figure 4C ). Significantly, in M1-⑀C cells, IL-10 treatment failed to up-regulate Fc␥RI expression. These results indicate that forced expression of PTP⑀C can inhibit not only IL-6-and LIF-induced signaling but also IL-10-induced JAK-STAT signaling. We also investigated the levels of tyrosine phosphorylation of JAK1 and TYK2 as determined by immunoprecipitationWestern blot analysis (data not shown). However, tyrosine phosphorylation of JAK1 or TYK2 was not detected following IL-10 stimulation of our cell lines. This finding is likely due to the low levels of JAK proteins that are activated in these cells. 
Effects of PTP⑀C expression on IFN-induced JAK-STAT signaling
Subunits of the IL-10-R, IL-10-RI, and CRF2-4 are structurally subgrouped as belonging to the class II cytokine receptor family with IFN-␣/␤-R and IFN-␥-R. 12, 13, 38 Given that PTP⑀C negatively regulates IL-10-R-mediated activation of STAT3, we investigated whether PTP⑀C is a common negative regulator of class II receptor-mediated JAK-STAT signaling. To address this issue, M1 stable clones were treated with IFN-␤ and IFN-␥ and analyzed for STAT1 tyrosine phosphorylation. In sharp contrast to IL-10 treatment, PTP⑀C did not block IFN-␤-and IFN-␥-induced tyrosine phosphorylation of STAT1. Figures 5A and 6A show the time courses of STAT1 tyrosine phosphorylation in M1 stable clones treated with IFN-␤ and IFN-␥, respectively. In each case, expression of PTP⑀C or PTP⑀C-DA did not affect STAT1 tyrosine phosphorylation, at least up to 3 or 6 hours. In addition to STAT1, tyrosine phosphorylation of JAK1 and STAT3 was not affected by PTP⑀C ( Figures 5B and 6B , and data not shown). IRF-1, a downstream effector of IFNs, is induced by IFNs through STAT1-STAT2 heterodimers and STAT1 homodimers. 39 As shown in Figures 5C and 6C , expression of IRF-1 mRNA was induced in M1-⑀C cells following IFN-␤ and IFN-␥ treatment, similar to what was observed in M1-Neo cells. SOCS-1 is also reported to be IFN inducible. 7, 40 Expression of SOCS-1 mRNA by IFNs was similarly induced in all stable clones ( Figures 5C and 6C ). Taken together, PTP⑀C does not appear to affect IFN-␥-induced JAK-STAT signaling.
Discussion
We and others have reported that expression of PTP⑀C is upregulated during macrophage differentiation and/or activation. As noted previously, PTP⑀C inhibited IL-10-induced STAT3 activation but not IFN-␥-induced STAT1 activation. It is well established that IFN-␥ and IL-10 have pleiotrophic effects on regulation of macrophage activation and de-activation, respectively. 10, 41, 42 In this context, PTP⑀C might play important roles in facilitating activation of macrophages and/or in maintaining activated states by selective down-regulation of the de-activating IL-10 signal. Because PTP⑀C is expressed not only in myeloid/monocytic lineages but also in lymphocytes (K.N. and N.T., unpublished results, March 2001), it would be of great interest and importance to determine whether PTP⑀C plays negative regulatory roles in cytokine signaling in lymphocytes.
In summary, results in this study reveal an inhibitory effect of PTP⑀C on STAT activation induced by IL-10 as well as by IL-6. Negative regulation by PTP⑀C does not involve SOCS family proteins (at least not SOCS-1 and -3) and may have a different mode of action from SHP-2. In contrast, PTP⑀C appears not to interfere with IFN-␤-and IFN-␥-induced JAK-STAT signaling. Our results indicate that PTP⑀C inhibition of JAK-STAT activation is not specified by particular JAKs or STATs. Instead, PTP⑀C-mediated suppression is selective for certain JAK-STAT signaling pathways through corresponding cytokine receptors such as gp130 and IL-10-R. Identification of target(s) of PTP⑀C-mediated suppression will enable us to fully understand the molecular basis for regulation of cytokine signaling. For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From
